霉酚酸酯与甲氨蝶呤作为保激素疗法对葡萄膜炎患者炎症的影响:一项随机临床试验
FAST试验在9个转诊眼科中心纳入216例需保激素免疫抑制治疗的非感染性葡萄膜炎成人患者,随机接受口服甲氨蝶呤25mg每周或口服霉酚酸酯3g每日;6个月治疗成功率甲氨蝶呤组66.7% vs 霉酚酸酯组57.1%,差异未达统计学显著(P=.20);后葡萄膜炎或全葡萄膜炎亚组甲氨蝶呤组成功率更高(P=.02),中间葡萄膜炎亚组霉酚酸酯组更高(交互作用P=.004)。
要点
- 总体6个月治疗成功率甲氨蝶呤组66.7% vs 霉酚酸酯组57.1%,差异未达统计学显著。
- 后葡萄膜炎或全葡萄膜炎亚组甲氨蝶呤组成功率74.4% vs 霉酚酸酯组55.3%,OR 2.35(95%CI 1.16-4.90)。
- 中间葡萄膜炎亚组甲氨蝶呤组成功率33.3% vs 霉酚酸酯组63.6%,OR 0.29(95%CI 0.08-1.05),交互作用P=.004。
核心结论
- 在非感染性葡萄膜炎成人患者中,与甲氨蝶呤相比,霉酚酸酯作为一线保激素治疗未能更优地控制炎症。
- 需进一步研究以确定两种药物是否根据葡萄膜炎解剖亚型而疗效不同。
研究设计与样本
- FAST(First-line Antimetabolites as Steroid-sparing Treatment)葡萄膜炎试验,随机临床试验。
- 2013年8月22日至2017年8月16日在印度、美国、澳大利亚、沙特阿拉伯和墨西哥的9个转诊眼科中心筛查265例需保激素免疫抑制治疗的非感染性葡萄膜炎成人患者。
- 随机分组:口服甲氨蝶呤25mg每周(n=107)或口服霉酚酸酯3g每日(n=109)。
- 共216例患者随机(中位年龄38岁;135例(62.5%)女性),194例(89.8%)完成6个月随访。
- 随访至2018年8月20日结束;患者随访至12个月,根据6个月结局继续原治疗或换用另一种抗代谢药。
主要发现
- 主要结局为6个月治疗成功,定义为双眼炎症控制、泼尼松每日不超过7.5mg且醋酸泼尼松龙1%滴眼液不超过2滴、且无因安全性或不可耐受导致的治疗失败。
- 6个月治疗成功:甲氨蝶呤组64例(66.7%)vs 霉酚酸酯组56例(57.1%),差异9.5%(95%CI -5.3%至21.8%),OR 1.50(95%CI 0.81至2.81),P=.20。
- 后葡萄膜炎或全葡萄膜炎患者中治疗成功:甲氨蝶呤组58例(74.4%)vs 霉酚酸酯组42例(55.3%),差异19.1%(95%CI 3.6%至30.6%),OR 2.35(95%CI 1.16至4.90),P=.02。
- 中间葡萄膜炎患者中治疗成功:甲氨蝶呤组6例(33.3%)vs 霉酚酸酯组14例(63.6%),差异-30.3%(95%CI -51.6%至1.1%),OR 0.29(95%CI 0.08至1.05),P=.07;交互作用P=.004。
- 肝酶升高是最常见的非严重实验室不良事件,甲氨蝶呤组14例(13.0%)vs 霉酚酸酯组8例(7.4%)。
关键数值与推荐
- 6个月治疗成功定义:双眼炎症控制、泼尼松每日不超过7.5mg、醋酸泼尼松龙1%滴眼液不超过2滴、无因安全性或不可耐受导致的治疗失败。
- 总体治疗成功OR 1.50(95%CI 0.81至2.81),P=.20。
- 后葡萄膜炎或全葡萄膜炎亚组治疗成功OR 2.35(95%CI 1.16至4.90),P=.02。
- 中间葡萄膜炎亚组治疗成功OR 0.29(95%CI 0.08至1.05),P=.07;交互作用P=.004。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究以确定两种药物是否根据葡萄膜炎解剖亚型而疗效不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Methotrexate and mycophenolate mofetil are commonly used immunomodulatory therapies for achieving corticosteroid-sparing control of noninfectious uveitis, but there is uncertainty about which drug is more effective. OBJECTIVE: To compare the effect of methotrexate and mycophenolate for achieving corticosteroid-sparing control of noninfectious intermediate uveitis, posterior uveitis, and panuveitis. DESIGN, SETTING, AND PARTICIPANTS: The First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial screened 265 adults with noninfectious uveitis requiring corticosteroid-sparing immunosuppressive therapy from 9 referral eye centers in India, the United States, Australia, Saudi Arabia, and Mexico between August 22, 2013, and August 16, 2017. Follow-up ended on August 20, 2018. INTERVENTIONS: Patients were randomized to receive oral methotrexate, 25 mg weekly (n = 107), or oral mycophenolate mofetil, 3 g daily (n = 109). MAIN OUTCOMES AND MEASURES: The primary outcome was treatment success at 6 months, which was defined as having control of inflammation in both eyes, no more than 7.5 mg prednisone daily and less than or equal to 2 drops of prednisolone acetate 1%, and no treatment failure due to safety or intolerability. Patients underwent follow-up to 12 months while receiving the same treatment or switched to the other antimetabolite, depending on their 6-month outcome. RESULTS: Among 216 patients who were randomized (median age, 38 years; 135 (62.5%) women), 194 (89.8%) completed follow-up through 6 months. Treatment success occurred in 64 (66.7%) patients in the methotrexate group vs 56 (57.1%) in the mycophenolate group (difference, 9.5% [95% CI, -5.3% to 21.8%]; odds ratio [OR], 1.50 [95% CI, 0.81 to 2.81]; P = .20). Among patients with posterior uveitis or panuveitis, treatment success was achieved in 58 (74.4%) in the methotrexate group vs 42 (55.3%) in the mycophenolate group (difference, 19.1% [95% CI, 3.6% to 30.6%]; OR, 2.35 [95% CI, 1.16 to 4.90]; P = .02); whereas among patients with intermediate uveitis treatment success occurred in 6 (33.3%) in the methotrexate group vs 14 (63.6%) in the mycophenolate group (difference, -30.3% [95% CI, -51.6% to 1.1%]; OR, 0.29 [95% CI, 0.08 to 1.05]; P = .07; P for interaction = .004). Elevated liver enzymes were the most common nonserious laboratory adverse event, occurring in 14 patients (13.0%) in the methotrexate group and 8 patients (7.4%) in the mycophenolate group. CONCLUSIONS AND RELEVANCE: Among adults with noninfectious uveitis, the use of mycophenolate mofetil compared with methotrexate as first-line corticosteroid-sparing treatment did not result in superior control of inflammation. Further research is needed to determine if either drug is more effective based on the anatomical subtype of uveitis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01829295.
引用
- Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial. JAMA. 2019. PMID: 31503307. doi:10.1001/jama.2019.12618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。